Caladrius Biosciences (CLBS) Earns Buy Rating from HC Wainwright

Caladrius Biosciences (NASDAQ:CLBS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Wednesday. They presently have a $12.00 price target on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 106.90% from the company’s current price.

Separately, Zacks Investment Research lowered Caladrius Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th.

Shares of Caladrius Biosciences (CLBS) opened at $5.80 on Wednesday. Caladrius Biosciences has a one year low of $2.63 and a one year high of $7.79. The stock has a market capitalization of $54.46, a P/E ratio of 2.75 and a beta of 1.46.

A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc. raised its position in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 155,380 shares of the biotechnology company’s stock after purchasing an additional 4,163 shares during the period. Vanguard Group Inc.’s holdings in Caladrius Biosciences were worth $723,000 as of its most recent filing with the Securities & Exchange Commission. 5.75% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at

About Caladrius Biosciences

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply